Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis

OBJECTIVE: To quantify comparative effectiveness of interleukin (IL)−12/23 antagonist (ustekinumab), IL-17A antagonists (secukinumab and ixekizumab), PDE4 inhibitor (apremilast) and tumour necrosis factor-alpha (TNF-α) inhibitors (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hanzhe, Wen, Jiajun, Alexander, G Caleb, Curtis, Jeffrey R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055145/
https://www.ncbi.nlm.nih.gov/pubmed/33863840
http://dx.doi.org/10.1136/rmdopen-2020-001399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055145/
https://www.ncbi.nlm.nih.gov/pubmed/33863840
http://dx.doi.org/10.1136/rmdopen-2020-001399

Ejemplares similares